Brady Stewart

Board Director

Director

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 1 buy · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€176k

▼ Sales (0 ops.)

—

Latest filing published 19 Feb 2026 for Evolus, Inc.. Read the official filing

Filing timeline

BuySale

Brady Stewart

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-2.5%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Brady Stewart: trading record in brief

Brady Stewart is a declared insider of Evolus, Inc. (board member), with filings sourced from SEC (Form 4). Over a trading history stretching from 5 January 2022 to 17 February 2026, the count stands at 6 filings.

The open-market record is one-sided, with 1 purchase worth €176k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 5 share grants.

On 19 February 2026 came the latest disclosure, a share grant in Evolus, Inc. The most recent open-market purchase was published on 18 August 2025, 426 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.